Celyad Oncology
- 0891.118.115
- BE0891118115
- Rue Emile Francqui 6, 1435 Mont-Saint-Guibert
- See the 21 companies at this address
- 24 July 2007
Profile
Official information from the CBE (FPS Economy).
Celyad Oncology is a Belgian company (Société anonyme) whose registered office is established at 1435 Mont-Saint-Guibert. Its main activity falls under “Autres services personnels” (NACE 96999).
- Legal form
- Société anonyme
- Legal situation
- Situation normale
- Date of incorporation
- 24 July 2007
- Main activity (NACE)
- 96999Autres services personnels
An activity that is, on the face of it, not covered by anti-money-laundering law. Learn more
Your risk analysis on this company
AML Company ran Celyad Oncology through your due diligence questionnaire. Here are the first findings.
What is the geographic exposure of the client and of its transactions?
Belgium only· Registered office published in the register
What is the company's solvency and lifecycle status?
Trading, no proceedings· Legal situation published in the register
Sanctions screening, politically exposed persons, ultimate beneficial owners, source of funds: AML Company runs them, documents them and keeps the proof in your file.
Run the full analysisThis preview is not a due diligence measure: it pre-qualifies questions from public data. Identifying the client and its ultimate beneficial owners requires documents collected and verified.
Establishments
1 active establishment unit declared with the CBE.
Finances & financial health
Multi-year summary extracted from the annual accounts filed with the Central Balance Sheet Office (CBSO, National Bank of Belgium).
Equity & result
| Financial year | Equity | Result | Turnover / gross margin | Headcount (FTE) |
|---|---|---|---|---|
| 2025 | €2,239,431 | -€564,911 | €21,000turnover | 10,5 |
| 2022 | €23,154,801 | -€39,622,435 | €1,314,292turnover | 65,8 |
| 2021 | €62,777,236 | -€29,460,427 | - | 87,1 |
| 2020 | – | – | - | – |
Financial ratios
Solvency, liquidity and profitability, computed year by year from the filed annual accounts.
Equity / balance sheet total
Current assets / debts due within one year
Result for the year / turnover
Operating result / turnover
Debts due after one year / balance sheet total
Result for the year / equity
Balance sheet structure
| Ratio | 2025 | 2022 | 2021 | Trend |
|---|---|---|---|---|
| Solvency | 55,5% 11,6% | 67,1% 14,3% | 81,5% | |
| Liquidity | 2,32 x 0,05 | 2,37 x 0,7 | 3,07 x | |
| Net margin | -2.690,1% 324,7% | -3.014,7% | - | |
| Operating margin | -2.858,4% 156% | -3.014,4% | - | |
| Long-term debt | 1,1% 9,2% | 10,3% 7,6% | 2,7% | |
| Return on equity | -25,2% 145,9% | -171,1% 124,2% | -46,9% |
Ratios computed by AML Company from the items filed in the balance sheet and the income statement. They are not filed figures as such: the underlying amounts appear in the key figures above.
Filing history (11)▾
| Financial year | Filing | Filing type | Model | Source |
|---|---|---|---|---|
| 01/01/2025 → 31/12/2025 | 11/06/2026 | Initial | m120-f-p | - |
| 01/01/2025 → 31/12/2025 | 10/06/2026 | Initial | m02-f | BNB |
| 01/01/2022 → 31/12/2022 | 05/06/2023 | Initial | m02-f | BNB |
| 01/01/2022 → 31/12/2022 | 05/06/2023 | Initial | m120-f-p | BNB |
| 01/01/2021 → 31/12/2021 | 24/05/2022 | Initial | m02-f | BNB |
| 01/01/2020 → 31/12/2020 | 25/05/2021 | Initial | m02-f | BNB |
| 01/01/2020 → 31/12/2020 | 25/05/2021 | Initial | m120-f-p | BNB |
| 01/01/2019 → 31/12/2019 | 05/06/2020 | Initial | m120-f-p | BNB |
| 01/01/2019 → 31/12/2019 | 05/06/2020 | Initial | m02-f | BNB |
| 01/01/2018 → 31/12/2018 | 26/06/2019 | Initial | m120-f-p | BNB |
| 01/01/2018 → 31/12/2018 | 25/06/2019 | Initial | m02-f | BNB |
Source: CBSO (NBB) filings, Belgian chart-of-accounts headings 9904 (result), 10/15 (equity), 9900 (gross margin), 9087 (workforce in FTE). Data available for filings from 2022 onwards.
Notices in the Belgian Official Gazette
Official acts and notices: incorporation, changes to the articles, appointments, dissolutions.
- DEMISSIONS, NOMINATIONS8 June 2026
- DEMISSIONS, NOMINATIONS12 March 2026
- DEMISSIONS, NOMINATIONS30 January 2026
- DEMISSIONS, NOMINATIONS29 December 2025
Source: Belgian Official Gazette (FPS Justice). The links open the official PDFs.
Frequently asked questions about Celyad Oncology
Quick answers on Celyad Oncology's identity, contact details and official CBE information.
What is Celyad Oncology's enterprise number (CBE)?
What is Celyad Oncology's VAT number?
Where is Celyad Oncology's registered office?
What is Celyad Oncology's legal form?
When was Celyad Oncology incorporated?
Is Celyad Oncology still active?
What is Celyad Oncology's main activity?
How can Celyad Oncology be contacted?
How many establishments does Celyad Oncology have?
Has Celyad Oncology filed its annual accounts?
Which official notices concern Celyad Oncology?
Is Celyad Oncology subject to anti-money-laundering obligations in Belgium?
Company timeline
Every dated event in the company's life, from filed accounts to notices published in the Belgian Official Gazette, in a single thread.
10 AI-analysed dimensions are not shown.
- 2026
- 11 June 2026Annual accounts filed·Financial year ended 31 December 2025 · Model m120-f-p
- 10 June 2026Annual accounts filed·Financial year ended 31 December 2025 · Model m02-fFiled accounts2026-00158811
- 2025
- 2024
Registry record since 7 September 2026
The KBO publishes its changes as a monthly delta and never restates the past: our record starts on that date, not at the company's incorporation. No change recorded since that date. A missing row says nothing about the company, only about how far back our record goes.
AI extraction of strategic AML data
The official notices in the Belgian Official Gazette are analysed by our AI engine to extract automatically the information that matters for your due diligence and your AML duties.
- Legal life
- Restructuring
- Capital
- Legal form
- Incorporation
- Directors
- Beneficial owners
- Registered office
- Company name
- Notarial deeds
Similar companies
Same business sector and geographic area.
Tools4Patient
NOVADIP BIOSCIENCES
Ncardia Holding
The Akkermansia Company
BiocSol
EsoBiotec
BIORES
DEVGEN
ABLYNX
Step it up
Full analysis unlocked.
Create an account to unlock the detailed analysis: health score, full history, alerts and PDF exports.